10-Q: XOMA Royalty Corporation Reports Q3 2024 Results, Includes Kinnate Acquisition Impact
Quarterly Report
XOMA Royalty Corporation's Q3 2024 results reflect a net loss, impacted by the Kinnate acquisition and royalty asset impairments, while also showing increased income from purchased receivables.
Summary
- XOMA Royalty Corporation reported a net loss of $17.2 million for the third quarter of 2024, and a net loss of $9.9 million for the first nine months of 2024.
- The company's operating expenses were $22.8 million for the quarter and $52.5 million for the nine-month period, including significant royalty purchase agreement asset impairments.
- Income from purchased receivables was $6.5 million for the quarter and $11.9 million for the nine-month period, indicating growth in revenue from royalty streams.
- The company recognized a gain of $19.3 million from the acquisition of Kinnate, which was accounted for as an asset acquisition.
- XOMA's cash and cash equivalents totaled $142.1 million as of September 30, 2024, with total assets of $223.3 million.
- The company's long-term debt stood at $108.1 million as of September 30, 2024, related to the Blue Owl Loan Agreement.
Sentiment
Score: 4
Explanation: The document presents mixed results. While there are positives such as the gain from the Kinnate acquisition and increased income from purchased receivables, the significant net loss, high operating expenses, and asset impairments temper the overall sentiment. The company's future is heavily reliant on the success of its partners' programs, which adds uncertainty.
Positives
- The company recognized a significant gain of $19.3 million from the Kinnate acquisition.
- Income from purchased receivables increased to $6.5 million in Q3 2024 and $11.9 million for the first nine months of 2024, indicating growth in royalty revenue.
- The company received $16.9 million in commercial payments from the Affitech CPPA during the nine months ended September 30, 2024.
- XOMA has $142.1 million in cash and cash equivalents, providing a solid financial base.
Negatives
- XOMA reported a net loss of $17.2 million for Q3 2024 and $9.9 million for the first nine months of 2024.
- The company incurred significant operating expenses of $22.8 million in Q3 2024 and $52.5 million for the first nine months of 2024.
- The company recorded $14 million and $23 million in royalty purchase agreement asset impairments for the three and nine months ended September 30, 2024, respectively.
- The company has an accumulated deficit of $1.2 billion as of September 30, 2024.
Risks
- The company's future income and revenue are dependent on the success of its partners and licensees.
- The company's ability to raise additional capital is subject to market conditions and other factors.
- The company's royalty and milestone payments are subject to the risks and uncertainties of the biotechnology industry.
- The company's long-term debt of $108.1 million could impact future financial flexibility.
- The company's operating expenses are significant and may impact profitability.
Future Outlook
The company expects income related to VABYSMO and OJEMDA to increase in future periods as sales increase. The company also expects G&A costs associated with the Kinnate acquisition to decrease in future periods as operations wind down. The company intends to use its existing capital resources to fund ongoing operations, repurchase common stock, and for working capital and other general corporate purposes.
Industry Context
XOMA operates in the biotech royalty aggregation space, which involves acquiring rights to future payments on drug development programs. This model is influenced by the success of clinical trials and commercialization of partnered drugs. The company's performance is tied to the broader biotech industry's ability to develop and commercialize new therapies.
Comparison to Industry Standards
- XOMA's royalty aggregation model is similar to other companies that acquire royalty streams, such as Royalty Pharma and Healthcare Royalty Partners. However, XOMA focuses on earlier-stage assets, which carries higher risk but also higher potential returns.
- The company's operating expenses are higher than some peers due to the costs associated with the Kinnate acquisition and ongoing operations.
- XOMA's revenue is primarily driven by milestone payments and royalties, which can be volatile and dependent on the success of its partners' programs. This is a common characteristic of royalty-focused companies.
- The company's debt level is significant, which is a common strategy for companies in this sector to fund acquisitions. However, it also increases financial risk.
Related Party Transactions
- As of September 30, 2024, BVF owned approximately 30.9% of the Company's total outstanding shares of common stock, and if all the Series X Convertible Preferred Stock were converted (without taking into account beneficial ownership limitations), BVF would own 51.5% of the Company's total outstanding shares of common stock. Due to its significant equity ownership, BVF is considered a related party of the Company.
Stakeholder Impact
- Shareholders may be concerned about the net loss and asset impairments, but encouraged by the gain from the Kinnate acquisition and increased income from purchased receivables.
- Employees may be impacted by the ongoing restructuring and cost-cutting measures.
- Customers and partners may be impacted by the company's strategic focus on royalty aggregation and the success of its partnered programs.
- Creditors may be impacted by the company's debt obligations and its ability to generate sufficient cash flow to service its debt.
Next Steps
- The company will continue to monitor the performance of its partnered programs and the commercialization of VABYSMO and OJEMDA.
- The company will continue to evaluate potential acquisitions of milestone payments and royalty streams.
- The company will continue to manage its operating expenses and debt obligations.
Key Dates
| Date | Description |
|---|---|
| 2006-11-01 | Date of the Takeda Collaboration Agreement. |
| 2015-09-03 | Date of the Anti-TGF Antibody License Agreement with Novartis. |
| 2016-12-21 | Date of the Royalty Sale Agreements with HCRP. |
| 2017-08-24 | Date of the Gevokizumab License Agreement with Novartis. |
| 2017-12-06 | Date of the License Agreement with Rezolute. |
| 2018-09-20 | Date of the Royalty Purchase Agreement with Agenus. |
| 2019-04-07 | Date of the Royalty Purchase Agreement with Aronora. |
| 2019-09-26 | Date of the Royalty Purchase Agreement with Palo. |
| 2021-03-22 | Date of the Royalty Purchase Agreement with Viracta. |
| 2021-10-06 | Date of the Commercial Payment Purchase Agreement with Affitech. |
| 2023-03-29 | Date of the Commercial Payment Purchase Agreement with Aptevo. |
| 2023-06-21 | Date of the Assignment and Assumption Agreement and Royalty Purchase Agreement with LadRx. |
| 2023-12-15 | Date of the Blue Owl Loan Agreement. |
| 2024-01-12 | Date of the Commercial Payment Purchase Agreement with Talphera. |
| 2024-02-16 | Date of the Kinnate Merger Agreement. |
| 2024-04-03 | Date of the Kinnate Merger Closing Date. |
| 2024-04-29 | Date of the Dar Royalty Purchase Agreements. |
| 2024-09-30 | End of the reporting period for the Q3 2024 results. |
| 2024-10-21 | Date of the Royalty Purchase Agreement with Twist Bioscience. |
Keywords
royalty aggregator, milestone payments, royalty streams, biotech, Kinnate acquisition, VABYSMO, financial results, asset impairment, commercial payments, debt financing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.